TH169587A - Ethyl derivatives that are modulators of MGLUR5 receptor activity. - Google Patents
Ethyl derivatives that are modulators of MGLUR5 receptor activity.Info
- Publication number
- TH169587A TH169587A TH1501002120A TH1501002120A TH169587A TH 169587 A TH169587 A TH 169587A TH 1501002120 A TH1501002120 A TH 1501002120A TH 1501002120 A TH1501002120 A TH 1501002120A TH 169587 A TH169587 A TH 169587A
- Authority
- TH
- Thailand
- Prior art keywords
- syndrome
- formula
- depression
- present
- chemical formula
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 claims abstract 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims abstract 4
- 239000000126 substance Substances 0.000 claims abstract 3
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 2
- 206010003805 Autism Diseases 0.000 claims abstract 2
- 208000020706 Autistic disease Diseases 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 2
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 2
- 210000001766 X chromosome Anatomy 0.000 claims abstract 2
- 150000008043 acidic salts Chemical class 0.000 claims abstract 2
- 230000003281 allosteric effect Effects 0.000 claims abstract 2
- 230000036506 anxiety Effects 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 150000004673 fluoride salts Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 230000002503 metabolic effect Effects 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 239000003607 modifier Substances 0.000 claims abstract 2
- 230000003287 optical effect Effects 0.000 claims abstract 2
- 150000003431 steroids Chemical class 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Abstract
การประดิษฐ์ปัจจุบันเกี่ยวข้องกับอนุพันธ์เอธินิล (ethylnyl) ของสูตร I (สูตรเคมี) I ที่ซึ่ง Y คือ N หรือ CH; R1 คือฟลูออไรหรือคลอไร; R2 คือไฮโดรเจนหรือเมธิล; หรือกับเกลือที่เติมกรดที่ยอมรับได้ทางเภสัชกรรม, กับสารผสมราวึมิก, หรือกับอีแนนทิ โอเมอร์ที่สอดคล้องของสิ่งนั้นและ/หรือออพติคัลไอไซเมอรืและ/หรือสเตอริโโซเมอรืของสิ่ง นั้น ในปัจจุบันได้ถูกพบอย่างน่าแปลใจว่าสารประกอบของสูตรทั้วไป I เป็นสารต้านเมตาโบ โทรปิกกลูตาเมตรีเวปเตอร์ (สารปรับอัลโลสเตอริกลบ) สำหรับใช้ในการรับษาอาการกังวล และอากเจ็บปวด, ภาวะซึมเสร้า, กลุ่มเศร้า, กลุ่มอาการโครโมโซม X เปราะบาง, กลุ่มโรคออทิสติก, โรค พาร์กินสัน, และดดรคกรดไหลย้อน (GERD) สิทธิบัตรยา The present invention involves an ethylnyl derivative of formula I (chemical formula) I, where Y is N or CH; R1 is fluoride or chloride; R2 is hydrogen or methyl; Or with a chemically acceptable acidic salt, with a rye mixture, or with an enanthi The corresponding ome of the thing and / or the optical isomer and / or the steroid of that present have been implicitly found that the compound of the whole formula Go I is a metabolic agent. Tropiglutametriwepters (Negative allosteric modifiers) for use in the treatment of anxiety And pain syndrome, depression, depression, fragile X chromosome syndrome, autism syndrome, Parkinson's disease, and acid reflux (GERD) drug patents.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH169587A true TH169587A (en) | 2017-10-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012611A (en) | PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
| PH12014501277A1 (en) | Kinase inhibitors | |
| AR100818A1 (en) | N- (CYANOMETIL) -4- (2- (4-MORFOLINOFENILAMINO) PIRIMIDIN-4-IL) BENZAMIDA | |
| CY1118439T1 (en) | NEW AGOMELATIN CYCLES | |
| ECSP15012804A (en) | ALCOXYPYRAZOLES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS | |
| CR20150254A (en) | CHEMICAL COMPOUNDS | |
| CY1111287T1 (en) | USE OF AGOMELATIN FOR TAKING MEDICINES INTENDED FOR TREATMENT OF GENERAL ANXIETY DISORDER | |
| EA201590699A1 (en) | Derivatives of ethylenes as modulators of MGLUR5 RECEPTOR ACTIVITY | |
| PH12014501278A1 (en) | Kinase inhibitors | |
| PH12018550212A1 (en) | Rotigotine behenate and preparation method and use thereof | |
| CU20120087A7 (en) | HYDROCHLORIDE SYNTHESIS AND CRYSTAL FORM OF 4- (3- (CIS-HEXAHYDROCICLOPENTA (C) PIRROL-2 (1H) -IL) PROPOXI) BENZAMIDE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| BR112015002320A2 (en) | ethinyl derivatives as modulators of mglur5 receptor activity | |
| TH169587A (en) | Ethyl derivatives that are modulators of MGLUR5 receptor activity. | |
| BR112015007991A2 (en) | ethinyl derivatives as modulators of mglur5 receptor activity | |
| EA201590415A1 (en) | DERIVATIVES OF DIAZEPINONA APPLICABLE FOR THE TREATMENT OF SYNDROME WITH Fragile X-CHROMOSOME, PARKINSON'S DISEASE OR REFLUX DISEASE | |
| TH167680A (en) | Ethyl derivatives as a modulator of activity of MGLUR5 receptor. | |
| ITTO20110652A1 (en) | COMPOUND DERIVED FROM THE ADENINE HAVING IMMUNO-MODULATING ACTION, ANTI-INFLAMMATORY AND ANTI-DOLUTION ACTION | |
| TH152834A (en) | The derivative [1,2,3] triazolo [4,5-D] pyrimidine is the active agent of the cannabinoid receptor. | |
| PL402331A1 (en) | Method of obtaining melphalan derivatives, derivatives obtained by this method, containing a pharmaceutical agent and medical use | |
| TH160969A (en) | Aryl ethanol derivatives | |
| TH154796A (en) | Kinase inhibitor | |
| TH167753A (en) | Benzylinda Sol Replaced for use as an inhibitor of BUB1 in the treatment of diseases that have increased abundant cell numbers (SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES). | |
| TH152458A (en) | New derivatives of dihydroquinolines-2-transfer | |
| TH131154A (en) | Urea derivatives as kinase inhibitors and their therapeutic use. | |
| TH146336A (en) | Pyridazinone compounds and their use as DAAO inhibitors |